CoChat

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Abstract

Background Ipilimumab is an approved treatment for patients with advanced melanoma. We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.Methods We did a double-blind, phase 3 trial in patients with stage III cutaneous melanoma (excluding lymph node metastasis ≤1 mm or in-transit metastasis) with adequate resection of lymph nodes (ie, the primary cutaneous melanoma must have been completely excised with adequate surgical margins) who had not received previous systemic therapy for melanoma from 91 hospitals located in 19 countries. Patients were randomly assigned (1:1), centrally by an interactive voice response system, to receive intravenous infusions of 10 mg/kg ipilimumab or placebo every 3 weeks for four doses, then every 3 months for up to 3 years. Using a minimisation technique, randomisation was stratified by disease stage and geographical region. The primary endpoint was recurrence-free survival, assessed by an independent review committee, and analysed by intention to treat. Enrollment is complete but the study is ongoing for follow-up for analysis of secondary endpoints. This trial is registered with EudraCT, number 2007-001974-10, and ClinicalTrials.gov, number NCT00636168.Findings Between July 10, 2008, and Aug 1, 2011, 951 patients were randomly assigned to ipilimumab (n=475) or placebo (n=476), all of whom were included in the intention-to-treat analyses. At a median follow-up of 2·74 years (IQR 2·28-3·22), there were 528 recurrence-free survival events (234 in the ipilimumab group vs 294 in the placebo group). Median recurrence-free survival was 26·1 months (95% CI 19·3-39·3) in the ipilimumab group versus 17·1 months (95% CI 13·4-21·6) in the placebo group (hazard ratio 0·75; 95% CI 0·64-0·90; p=0·0013); 3-year recurrence-free survival was 46·5% (95% CI 41·5-51·3) in the ipilimumab group versus 34·8% (30·1-39·5) in the placebo group. The most common grade 3-4 immune-related adverse events in the ipilimumab group were gastrointestinal (75 [16%] vs four [<1%] in the placebo group), hepatic (50 [11%] vs one [<1%]), and endocrine (40 [8%] vs none). Adverse events led to discontinuation of treatment in 245 (52%) of 471 patients who started ipilimumab (182 [39%] during the initial treatment period of four doses). Five patients (1%) died due to drug-related adverse events. Five (1%) participants died because of drug-related adverse events in the ipilimumab group; three patients died because of colitis (two with gastrointestinal perforation), one patient because of myocarditis, and one patient because of multiorgan failure with Guillain-Barré syndrome.Interpretation Adjuvant ipilimumab significantly improved recurrence-free survival for patients with completely resected high-risk stage III melanoma. The adverse event profile was consistent with that observed in advanced melanoma, but at higher incidences in particular for endocrinopathies. The risk-benefit ratio of adjuvant ipilimumab at this dose and schedule requires additional assessment based on distant metastasis-free survival and overall survival endpoints to define its definitive value.Funding Bristol-Myers Squibb.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(15)70122-1

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 1,262

Metadata

Authors
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Konto, C., Hoos, A., de Pril, V., Gurunath, R. K., de Schaetzen, G., Suciu, S., & Testori, A.
Affiliations
  • Institut Gustave Roussy (FR)
  • Aix-Marseille Université (FR)
  • University Hospital Zurich (CH)
  • Memorial Sloan Kettering Cancer Center (US)
  • Aarhus University Hospital (DK)
  • Angeles Clinic and Research Institute (US)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • Oncology Specialists (US)
  • Istituti Fisioterapici Ospitalieri (IT)
  • Cross Cancer Institute (CA)
  • Moffitt Cancer Center (US)
  • University of Siena (IT)
  • Bristol-Myers Squibb (United States) (US)
  • European Organisation for Research and Treatment of Cancer (BE)
  • European Institute of Oncology (IT)
Corresponding author
Eggermont, Alexander M M
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-05
Volume
16
Issue
5
Pages
522-530
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2070825440
Cited by
1,262
References
24
Citations by year
2026: 33 · 2025: 52 · 2024: 60 · 2023: 104 · 2022: 103 · 2021: 116 · 2020: 133 · 2019: 150 · 2018: 154 · 2017: 151 · 2016: 156 · 2015: 42
FWCI
73.22
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Funders
Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
ipilimumab, adjuvant therapy, stage III melanoma, cutaneous melanoma, recurrence-free survival, CTLA-4 blockade, immune checkpoint inhibitors, R0 resection, high-risk melanoma, progression-free survival, overall survival, safety and tolerability
MeSH terms
Ipilimumab, Adjuvants, Immunologic, Adult, Aged, Antibodies, Monoclonal, Combined Modality Therapy, Double-Blind Method, Female, Humans, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(15)70122-1
The paper
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Konto, C., Hoos, A., de Pril, V., Gurunath, R. K., . . . Testori, A. (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)70122-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.